Cytek Biosciences (CTKB) Stock: Buy, Sell, or Hold?
CTKB - Cytek Biosciences, Inc. Common Stock
$5.50
0.16 (3.00%)
▲
5d:
+1.95%
30d:
-3.68%
90d:
+20.61%
BUY
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 04, 2026
12d
Get Alerted When CTKB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CTKB shows positive signals but monitor for confirmation. Market pricing in 9.8% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CTKB shows positive signals but monitor for confirmation. Market pricing in 9.8% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CTKB is currently trading at $5.50, which is considered fair relative to its 30-day fair value range of $5.15 to $5.76. From a valuation perspective, the stock is trading at a premium (Forward PE: 78.6) compared to its historical average (59.4). At these levels, the market is pricing in 9.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CTKB is in a strong uptrend. The price is approaching resistance at $5.55. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CTKB scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CTKB is in a strong uptrend. The price is approaching resistance at $5.55. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CTKB scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.15 -
$5.76
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
77.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (62/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($5.56)
- NEUTRAL: Trading at premium valuation - market expects 9.8% growth which is achievable
- BULLISH: Bottoming setup score 62/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$5.15 -
$5.76
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$5.05
Resistance Level
$5.56
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
78.57
Wall Street Target
$5.56
(+1.1%)
Revenue Growth (YoY)
5.6%
Earnings Growth (YoY)
73.5%
Profit Margin
-39.0%
Valuation Premium vs History
+9.8% premium
PE vs Historical
78.6 vs 59.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+9.8%
(market-implied from PE analysis)
1-Year Target
$6.04
(+10%)
2-Year Target
$6.63
(+21%)
3-Year Target
$7.28
(+32%)
3-Yr Target (if PE normalizes)
(PE: 79→59)
PE COMPRESSION
$5.50
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: October 22, 2026 4:41 AM ET
Data refreshes hourly during market hours. Next update: 5:41 AM
Data refreshes hourly during market hours. Next update: 5:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTKB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
31 analysts |
$59 | 50 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
29 analysts |
$363 | 37 SELL |
|
MDT
Medtronic PLC |
BUY
29 analysts |
$105 | 43 HOLD |
|
AXGN
Axogen Inc |
STRONG BUY
12 analysts |
$54 | 75 BUY |
|
TNDM
Tandem Diabetes Care Inc |
BUY
25 analysts |
$28 | 54 HOLD |
